Genomic Medicine in the Developing World: Cancer Spectrum, Cumulative Risk and Survival Outcomes for Lynch Syndrome Variant Heterozygotes with Germline Pathogenic Variants in the and Genes

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2025 Jan 8

PMID 39767815

Authors

Lutricia Ndou

Ramadhani Chambuso

Ursula Algar

Adam Boutall

Paul Goldberg

Raj Ramesar

Affiliations

Soon will be listed here.

Abstract

: Although genetic testing has improved our ability to diagnose Lynch syndrome (LS), there is still limited information on the extent of variations in the clinical and genetic landscape among LS variant heterozygotes (LSVH) in Africa. We sought to investigate the cancer spectrum, cumulative risk, and survival outcomes of LSVH with pathogenic/likely pathogenic variants (P/LPVs) in the and genes using a LS registry in South Africa over the last 30 years. : A retrospective study was conducted to retrieve demographic, clinical, and genetic data of all LSVH with P/LPVs in the and genes from our LS registry. Genetic data were analyzed according to cancer spectrum, cumulative risk, and crude survival. We used the Chi-squared and -test to assess differences between groups, and Kaplan-Meier survival analyses were used to analyze the cumulative risk and crude survival outcomes. A -value < 0.05 at a 95% confidence interval was considered statistically significant. : We analyzed a total of 577 LSVH from 109 families. About 450 (78%) and 127 (22%) LSVH harbored a disease-causing mutation in and , respectively. A South African founder PV (:c.1528C>T) accounted for 74% (n = 426) of all LSVH. CRC was the most common diagnosed cancer in both and LSVH. LSVH had a younger age at cancer diagnosis than LSVH (43 vs. 47 years, respectively, = 0.015). Extracolonic cancers were predominantly higher in female LSVH (n = 33, 35%) than in male LSVH (n = 8, 7%) with the :c.1528C>T founder PV. The cumulative risk of any cancer and CRC at any age was higher in LSVH than in LSVH ( = 0.020 and = 0.036, respectively). LSVH with the :c.1528C>T PV had a better 10-year overall survival after the first cancer diagnosis, particularly for CRC. : LSVH with P/LPVs in the and genes exhibited significant gene- and sex-specific differences in cancer spectrum, cumulative risk and survival outcomes. Cancer risk and survival estimates described in this study can be used to guide surveillance and genetic counselling for LSVH in our population.

References

Alvarez K, Orellana P, De la Fuente M, Canales T, Pinto E, Heine C . Spectrum and Frequency of Tumors, Cancer Risk and Survival in Chilean Families with Lynch Syndrome: Experience of the Implementation of a Registry. J Clin Med. 2020; 9(6). PMC: 7356331. DOI: 10.3390/jcm9061861. View

Abu Shtaya A, Kedar I, Mattar S, Mahamid A, Basel-Salmon L, Barhom S . The Diagnostic Yield and Implications of Targeted Founder Pathogenic Variant Testing in an Israeli Cohort. Cancers (Basel). 2024; 16(1). PMC: 10777957. DOI: 10.3390/cancers16010094. View

Dominguez-Valentin M, Sampson J, Seppala T, Ten Broeke S, Plazzer J, Nakken S . Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. Genet Med. 2019; 22(1):15-25. PMC: 7371626. DOI: 10.1038/s41436-019-0596-9. View

Scott R, McPhillips M, Meldrum C, Fitzgerald P, Adams K, Spigelman A . Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet. 2000; 68(1):118-127. PMC: 1234904. DOI: 10.1086/316942. View

Kennelly R, Kavanagh D, Hogan A, Winter D . Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol. 2008; 9(4):385-91. DOI: 10.1016/S1470-2045(08)70100-1. View

Burn J, Sheth H, Elliott F, Reed L, Macrae F, Mecklin J . Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial. Lancet. 2020; 395(10240):1855-1863. PMC: 7294238. DOI: 10.1016/S0140-6736(20)30366-4. View

Vasen H, Stormorken A, Menko F, Nagengast F, Kleibeuker J, Griffioen G . MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol. 2001; 19(20):4074-80. DOI: 10.1200/JCO.2001.19.20.4074. View

Guo M, Fang Z, Chen B, Songyang Z, Xiong Y . Distinct dosage compensations of ploidy-sensitive and -insensitive X chromosome genes during development and in diseases. iScience. 2023; 26(2):105997. PMC: 9926305. DOI: 10.1016/j.isci.2023.105997. View

Goldberg P, Madden M, Harocopos C, Felix R, Westbrook C, Ramesar R . In a resource-poor country, mutation identification has the potential to reduce the cost of family management for hereditary nonpolyposis colorectal cancer. Dis Colon Rectum. 1998; 41(10):1250-3; discussion 1253-5. DOI: 10.1007/BF02258223. View

10.

Dowty J, Win A, Buchanan D, Lindor N, Macrae F, Clendenning M . Cancer risks for MLH1 and MSH2 mutation carriers. Hum Mutat. 2012; 34(3):490-7. PMC: 3887142. DOI: 10.1002/humu.22262. View

11.

Caiazza F, Ryan E, Doherty G, Winter D, Sheahan K . Estrogen receptors and their implications in colorectal carcinogenesis. Front Oncol. 2015; 5:19. PMC: 4313613. DOI: 10.3389/fonc.2015.00019. View

12.

Vorobiof D, Sitas F, Vorobiof G . Breast cancer incidence in South Africa. J Clin Oncol. 2001; 19(18 Suppl):125S-127S. View

13.

Abancens M, Bustos V, Harvey H, McBryan J, Harvey B . Sexual Dimorphism in Colon Cancer. Front Oncol. 2020; 10:607909. PMC: 7759153. DOI: 10.3389/fonc.2020.607909. View

14.

Watson P, Lynch H . The tumor spectrum in HNPCC. Anticancer Res. 1994; 14(4B):1635-9. View

15.

Wang D, Tang L, Wu Y, Fan C, Zhang S, Xiang B . Abnormal X chromosome inactivation and tumor development. Cell Mol Life Sci. 2020; 77(15):2949-2958. PMC: 11104905. DOI: 10.1007/s00018-020-03469-z. View

16.

Berry S, Ngo L, Samelson E, Kiel D . Competing risk of death: an important consideration in studies of older adults. J Am Geriatr Soc. 2010; 58(4):783-7. PMC: 2873048. DOI: 10.1111/j.1532-5415.2010.02767.x. View

17.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

18.

Torres Stone R, Waring M, Cutrona S, Kiefe C, Allison J, Doubeni C . The association of dietary quality with colorectal cancer among normal weight, overweight and obese men and women: a prospective longitudinal study in the USA. BMJ Open. 2017; 7(6):e015619. PMC: 5734399. DOI: 10.1136/bmjopen-2016-015619. View

19.

Vasen H, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I . Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet. 2007; 44(6):353-62. PMC: 2740877. DOI: 10.1136/jmg.2007.048991. View

20.

Doubeni C, Laiyemo A, Major J, Schootman M, Lian M, Park Y . Socioeconomic status and the risk of colorectal cancer: an analysis of more than a half million adults in the National Institutes of Health-AARP Diet and Health Study. Cancer. 2012; 118(14):3636-44. PMC: 3422782. DOI: 10.1002/cncr.26677. View